Back to Authors

Birchall, Martin

https://orcid.org/0000-0002-9211-1722

Mayo Clinic

Royal National Throat Nose and Ear Hospital

Citations 3

A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies
Davies, Benjamin M. , Rikabi, Sarah , Wartolowska, Karolina , French, Anna , MacLaren, Robert E. , Williams, David , Bure, Kim, Pinedo‐Villanueva, Rafael , Mathur, Anthony , Birchall, Martin , Snyder, Evan , Reeve, Brock , Morrey, Mark, Smith, James Andrew Buchan , Morrey, Mark E. , Atala, Anthony , Brindley, David A.

Journal of Tissue Engineering | August 11, 2017 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2041731417724413 Get It

Cellular therapies, such as stem cell–based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments.
The current status of human laryngeal transplantation in 2017: A state of the field review
Krishnan, Giri , Du, Charles, Fishman, Jonathan, Foreman, Andrew , Farwell, G., Belafsky, Peter C. , Krishnan, Suren , Birchall, Martin , Lott, David G.

The Laryngoscope | February 22, 2017 | Volume: 127 | Issue: 8 | Pages: 1861-1868

10.1002/lary.26503 Get It

ObjectivesHuman laryngeal allotransplantation has long been contemplated as a surgical option following laryngectomy, but there is a paucity of information regarding the indications, surgical procedure, and patient outcomes. Our objectives were to identify all human laryngeal allotransplants that have been undertaken and reported in the English literature and to evaluate the success of the procedure.Data SourcesMEDLINE, Embase, Current Index to Nursing and Allied Health Literature, Web of Science and Scopus, and the Gray literature.Review MethodsA comprehensive search strategy was undertaken across multiple databases. Inclusion criteria were case reports of patients who had undergone human laryngeal allotransplantation. Information regarding indications, operative techniques, complications, graft viability, and functional outcomes were extracted.ResultsA total of 5,961 articles, following removal of duplicates, matched the search criteria and were screened, with five case reports relating to two patients, ultimately fulfilling the entry criteria.ConclusionsTwo laryngeal transplants have been reported in the medical literature. Although both patients report improved quality of life relating to their ability to communicate with voice, further research is necessary to shape our understanding of this complicated operation, its indications, and its functional outcomes. Laryngoscope, 127:1861–1868, 2017
Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study
Davies, Benjamin M. , Rikabi, Sarah , French, Anna , Pinedo‐Villanueva, Rafael , Wartolowska, Karolina , Judge, Andrew , MacLaren, Robert E. , Mathur, Anthony , Williams, David , Wall, Ivan , Birchall, Martin , Reeve, Brock , Barker, Richard , Cui, Zhanfeng , Bure, Kim, Snyder, Evan Y., Carr, Andrew , Morrey, Mark E. , Atala, Anthony , Furniss, Dominic , Karp, Jeffrey M. , Price, Andrew James , Brindley, David A.

Journal of Tissue Engineering | September 23, 2014 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1177/2041731414551764 Get It

There has been a large increase in basic science activity in cell therapy and a growing portfolio of cell therapy trials. However, the number of industry products available for widespread clinical use does not match this magnitude of activity. We hypothesize that the paucity of engagement with the clinical community is a key contributor to the lack of commercially successful cell therapy products. To investigate this, we launched a pilot study to survey clinicians from five specialities and to determine what they believe to be the most significant barriers to cellular therapy clinical development and adoption. Our study shows that the main concerns among this group are cost-effectiveness, efficacy, reimbursement, and regulation. Addressing these concerns can best be achieved by ensuring that future clinical trials are conducted to adequately answer the questions of both regulators and the broader clinical community.